Welcome to our dedicated page for Amrize SEC filings (Ticker: AMRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amrize Ltd (NYSE: AMRZ) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. As a Switzerland-incorporated issuer listed on the New York Stock Exchange and the SIX Swiss Exchange, Amrize files reports with the U.S. Securities and Exchange Commission that give investors structured information about its operations and financial condition.
Recent Form 8-K filings from Amrize have reported quarterly financial results and related investor materials. These filings typically reference earnings press releases and investor presentations that discuss revenue by segment, non-GAAP metrics such as Adjusted EBITDA, Free Cash Flow, Net Debt and Net Leverage Ratio, and commentary on the performance of the Building Materials and Building Envelope segments. They also confirm details such as the company’s jurisdiction of incorporation in Switzerland and its principal executive office location in Zug.
On this page, investors can monitor new 8-K filings as they are released, along with other SEC forms when available, such as annual and quarterly reports that provide more comprehensive detail on Amrize’s business, risk factors and segment information. Filings related to capital structure, such as debt issuance, and any documents reporting significant events or transactions, are also part of the regulatory record.
Stock Titan enhances these filings with AI-powered summaries designed to explain the main points of lengthy documents in clear language. This can help readers quickly understand key topics such as segment performance, changes in leverage, major investments, or strategic initiatives like the ASPIRE program, while still allowing direct access to the full original filings for detailed analysis.
Amrize Ltd (AMRZ) officer purchased shares on 08/13/2025. The reporting person, identified as an officer serving as Chief Supply Chain Officer, acquired 3,000 ordinary shares at a reported price of $49.63 per share. After the purchase the officer directly beneficially owned 23,232 shares. The purchase was executed in Swiss francs at CHF 39.87 per share and converted using the transaction-day rate of USD 1.00 = CHF 0.8034. The Form 4 was signed by an attorney-in-fact, Hans Weinburger, on 08/14/2025. The filing records a purchase transaction coded "P" and documents the change in direct ownership without additional derivative activity disclosed.
Wilbur Maria Cristina Alapag, a director of Amrize Ltd (AMRZ), reported an equity award on 08/11/2025: a grant of 2,958 restricted stock units under the Amrize Ltd 2025 Omnibus Incentive Plan. The award was issued with a $0 purchase price and will vest on the earlier of the one-year anniversary of the grant date or the issuer's next regular annual meeting of shareholders.
After the reported transaction the reporting person held 3,148 ordinary shares beneficially. The filing is a routine director equity award that documents the grant size, vesting condition, and post-transaction ownership level.
Amrize Ltd director Robert S. Rivkin reported the acquisition of 2,958 ordinary shares in the form of a restricted stock unit (RSU) award under the Amrize Ltd 2025 Omnibus Incentive Plan. The award is recorded at a $0 price and is held directly following the transaction.
The RSUs vest on the earlier of the one-year anniversary of the grant and the issuer's next regular annual meeting of shareholders. The Form 4 shows the reported transaction date as 08/11/2025 and indicates the filing was made by one reporting person with an attorney-in-fact noted on the form.
Amrize Ltd (AMRZ) reports that director Roth Pellanda Katja Nicole received 2,958 ordinary shares as a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan. The transaction is recorded as an acquisition and the award shows a reported price of $0, indicating the shares were granted rather than purchased.
The award vests on the earlier of the one-year anniversary of the grant date and the issuer's next regular annual meeting of shareholders, and following the transaction the reporting person beneficially owns 2,958 shares directly. No derivative securities were reported in this filing.
Oleas Jurg Amadeo, a director of Amrize Ltd (AMRZ), was granted 2,958 restricted stock units under the Amrize Ltd 2025 Omnibus Incentive Plan on 08/11/2025 at a reported price of $0.
The award vests on the earlier of the one-year anniversary of the grant or the issuer's next regular annual meeting. After the grant, the reporting person beneficially owns 21,073 ordinary shares directly.
Amrize Ltd (AMRZ) reported a restricted stock unit award to director Michael E. McKelvy consisting of 2,958 ordinary shares granted under the Amrize Ltd 2025 Omnibus Incentive Plan. The grant is recorded as having a $0 price because it is a restricted stock unit award, and the reporting person is shown as the direct beneficial owner of 2,958 shares following the award.
The award vests on the earlier of the one-year anniversary of the grant date or the company’s next regular annual meeting of shareholders, which means the shares are subject to time-based vesting conditions before becoming transferable.
Amrize Ltd (AMRZ) disclosed that director Holli C. Ladhani received a restricted stock unit award for 2,958 ordinary shares under the Amrize Ltd 2025 Omnibus Incentive Plan. The award was reported as an acquisition on 08/11/2025 at a reported price of $0 and is shown as direct beneficial ownership of 2,958 shares following the transaction. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the issuer’s next regular annual meeting of shareholders, meaning the shares may convert to ownership within that timeframe if vesting conditions are met.
Gibson Dwight Audley Konrad, identified as a director of Amrize Ltd (AMRZ), was granted 2,958 ordinary shares as a restricted stock unit award under the Amrize Ltd 2025 Omnibus Incentive Plan. The award was recorded as an acquisition at a $0 price and is held directly by the reporting person. The RSUs vest on the earlier of the one-year anniversary of the grant date or the issuer's next regular annual meeting of shareholders. Following the reported transaction, the reporting person beneficially owns 2,958 shares.
Amrize Ltd director Nicholas C Gangestad was awarded 2,958 restricted stock units (RSUs) under the Amrize Ltd 2025 Omnibus Incentive Plan. The award is reported as an acquisition that results in 2,958 ordinary shares beneficially owned directly following the transaction and is recorded at a $0 price.
The RSUs vest on the earlier of the one‑year anniversary of the grant date and the issuer's next regular annual meeting of shareholders, creating a time‑based grant that converts to ordinary shares on vesting. No derivative securities were reported in this filing and no additional cash or material financial terms beyond the vesting condition and share count are disclosed.
Amrize Ltd (AMRZ) director Drew Theresa J was granted 2,958 restricted stock units (RSUs) under the Amrize Ltd 2025 Omnibus Incentive Plan, recorded as an acquisition on 08/11/2025. The award was issued at a $0 price and is reported as 2,958 ordinary shares beneficially owned by the reporting person following the transaction.
The RSUs vest on the earlier of the one-year anniversary of the grant and the issuer's next regular annual meeting of shareholders, creating alignment between the director and shareholders while representing a routine equity-compensation award that is modest in absolute size relative to typical market capitalization impacts. The Form 4 was filed by a single reporting person.